Cologuard has gone bilingual. The popular mail-in colorectal cancer screening test from Exact Sciences has a new ...
Exact Sciences EXAS continues to make significant progress with its Cologuard test and efforts to expand Oncotype DX overseas. Advancements in the key pipeline programs are highly promising.
Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue ...
Exact Sciences Corporation’s EXAS robust efforts to enhance Cologuard’s growth are poised to help it grow in the upcoming quarters. The company aims to introduce novel solutions that will ...
Exact Sciences (EXAS) identifies more than 100 opportunities with payers and health systems to address the care gaps with Cologuard through screening programs. Exact Sciences (EXAS) ...
EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection ...
This optimism is further bolstered by the potential for a favorable reimbursement rate proposal for Exact Sciences’ Cologuard 2.0 test, despite a close vote at the CDLT Panel. Additionally, the ...